Showing 2511-2520 of 4063 results for "".
- Marinomed Biotech to Launch Carragelose Eye Drops in Europe in 2024https://modernod.com/news/marinomed-biotech-to-launch-carragelose-eye-drops-in-europe-in-2024/2481677/Marinomed Biotech announced it plans to introduce a new Carragelose eye drop product (MAM-1001-3) with an expected market launch in Austria targeted for the first half of 2024. Marinomed said it has started a business development process to identify partners for the marketing of the product
- Cellusion Raises $21 Million to Advance iPS Cell-Derived Corneal Endothelial Cell Substitutehttps://modernod.com/news/cellusion-raises-21-million-to-advance-ips-cell-derived-corneal-endothelial-cell-substitute/2481659/Tokyo-based Cellusion announced that it has raised 2.83 billion yen ($21 million USD) in Series C Round financing. The funding will be used to promote its lead program—the development of iPS cell-derived corneal endothelial cell substitute (CLS001) to resolve the challenge of
- SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conferencehttps://modernod.com/news/sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference/2481654/With a goal to improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference taking place from June 9-11 in Manchester, England. Three-Year Myopia Control Eff
- Dr. Louis R. Pasquale Winner of the Glaucoma Foundation's 2023 Robert Ritch Awardhttps://modernod.com/news/dr-louis-r-pasquale-winner-of-the-glaucoma-foundations-2023-robert-ritch-award/2481629/Louis R. Pasquale, MD, FARVO, has been named the 2023 recipient of The Glaucoma Foundation’s (TGF) Robert Ritch Award for Innovation and Excellence in Glaucoma. Created in 2008, the award recognizes the contributions of individuals who have played a significant and unique role in promoting
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol
- Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-completes-enrollment-ahead-of-schedule-in-its-phase-12a-trial-of-ea-2353-for-retinitis-pigmentosa/2481594/Endogena Therapeutics has announce that it has completed patient enrollment ahead of schedule in its phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation stage completed in April, the ongoing trial is now in the expansion cohort stag
- Alcon Announces its Largest Scientific Presence at ASCRS 2023 and Expands Image-Guided Connectivityhttps://modernod.com/news/alcon-announces-its-largest-scientific-presence-at-ascrs-2023-and-expands-image-guided-connectivity/2481588/Alcon announced its surgical ophthalmic presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2023 annual meeting, taking place May 5-8 in San Diego, and stated that its innovations will be featured in more studies than ever in its history.[1] Alcon ASCRS even
- Aurion Biotech to Present Clinical Trial Results at the 2023 ASCRS Annual Meetinghttps://modernod.com/news/aurion-biotech-to-present-clinical-trial-results-at-the-2023-ascrs-annual-meeting/2481586/Aurion Biotech announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held May 5-8, 2023 in San Diego, California. At Eyecelerator and ASCRS 2023, data will be presented from the comp
- Nanoscope Therapeutics Presents Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of RP at ARVOhttps://modernod.com/news/nanoscope-therapeutics-presents-key-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-rp-at-arvo/2481583/Nanoscope Therapeutics announced the presentation of key data from its phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARV
- ViaLase to Present Clinical Data at the 2023 ASCRS Annual Meetinghttps://modernod.com/news/vialase-to-present-clinical-data-at-the-2023-ascrs-annual-meeting/2481582/ViaLase announced that it will present first-in-human clinical data and a technology overview during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held May 5-8, 2023 in San Diego, California. Presentati